A long period of EGCG treatment reduced obesity development, and symptoms related to metabolic diseases and fatty liver through reduced lipid absorption and decreased inflammatory cytokines such as TNF-α, IL-1β, and IL-6 [27]. Here, IL1B is linked to obesity due to melanocortin 4 receptor deficiency.